{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:38:10Z","timestamp":1787510290793,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Daiichi Sankyo, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Diffuse tenosynovial giant cell tumor (D-TGCT) is a benign neoplasm with locally aggressive potential of the synovium, bursae, and tendon sheaths. This review summarizes the current treatment landscape for D-TGCT, with a focus on systemic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Surgery is the primary treatment option for tenosynovial giant cell tumor (TGCT), but there is a high risk of recurrence and associated morbidity, particularly for patients with advanced D-TGCT. Systemic therapies targeting the colony-stimulating factor 1 receptor (CSF1R) have resulted in positive tumor response, improved function, and decreased symptoms. For an alternative to surgery, the CSF1R inhibitors pexidartinib and vimseltinib are approved in the United States for TGCT, and other CSF1R inhibitors are in clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>CSF1R inhibitors represent a significant evolution in therapeutic strategies for D-TGCT. The potential risks and benefits of available treatments should be carefully considered in collaboration with a bone tumor\u2013experienced, multidisciplinary team to determine the best course of care. Increased D-TGCT awareness and support through patient advocacy groups have helped to reshape the patient journey.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-025-01679-x","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:15:00Z","timestamp":1747732500000},"page":"844-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Medical Management of Tenosynovial Giant Cell Tumor"],"prefix":"10.1007","volume":"27","author":[{"given":"Emanuela","family":"Palmerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis John","family":"Hornicek\u00a0Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"102491","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti S, Durr HR, Schaefer IM, Woertler K, Haas R, Trama A, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102491.","journal-title":"Cancer Treat Rev"},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","volume":"17","author":"M Brahmi","year":"2016","unstructured":"Brahmi M, Vinceneux A, Cassier PA. Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: targeting the CSF1\/CSF1R axis. Curr Treat Options Oncol. 2016;17:10. https:\/\/doi.org\/10.1007\/s11864-015-0385-x.","journal-title":"Curr Treat Options Oncol"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3899\/jrheum.160816","volume":"44","author":"V Ehrenstein","year":"2017","unstructured":"Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski R, et al. Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol. 2017;44:1476\u201383. https:\/\/doi.org\/10.3899\/jrheum.160816.","journal-title":"J Rheumatol"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","volume":"88","author":"MJL Mastboom","year":"2017","unstructured":"Mastboom MJL, Verspoor FGM, Verschoor AJ, Uittenbogaard D, Nemeth B, Mastboom WJB, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88:688\u201394. https:\/\/doi.org\/10.1080\/17453674.2017.1361126.","journal-title":"Acta Orthop"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/TUB-220005","volume":"44","author":"WD Tap","year":"2022","unstructured":"Tap WD, Healey JH. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor. Tumour Biol. 2022;44:239\u201348. https:\/\/doi.org\/10.3233\/TUB-220005.","journal-title":"Tumour Biol"},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/gcc.22807","volume":"59","author":"J Ho","year":"2020","unstructured":"Ho J, Peters T, Dickson BC, Swanson D, Fernandez A, Frova-Seguin A, et al. Detection of CSF1 rearrangements deleting the 3\u2019 UTR in tenosynovial giant cell tumors. Genes Chromosomes Cancer. 2020;59:96\u2013105. https:\/\/doi.org\/10.1002\/gcc.22807.","journal-title":"Genes Chromosomes Cancer"},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.2174\/1573394715666190618121649","volume":"27","author":"Q Xun","year":"2020","unstructured":"Xun Q, Wang Z, Hu X, Ding K, Lu X. Small-molecule CSF1R inhibitors as anticancer agents. Curr Med Chem. 2020;27:3944\u201366. https:\/\/doi.org\/10.2174\/1573394715666190618121649.","journal-title":"Curr Med Chem"},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690\u20135. https:\/\/doi.org\/10.1073\/pnas.0507321103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","volume":"16","author":"NM Bernthal","year":"2021","unstructured":"Bernthal NM, Spierenburg G, Healey JH, Palmerini E, Bauer S, Topp Study Group. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet J Rare Dis. 2021;16:191. https:\/\/doi.org\/10.1186\/s13023-021-01820-6.","journal-title":"Orphanet J Rare Dis"},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2196\/ijmr.9325","volume":"7","author":"MJ Mastboom","year":"2018","unstructured":"Mastboom MJ, Planje R, van de Sande MA. The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life. Interact J Med Res. 2018;7:e4. https:\/\/doi.org\/10.2196\/ijmr.9325.","journal-title":"Interact J Med Res"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13023-021-01883-5","volume":"16","author":"J Lopez-Bastida","year":"2021","unstructured":"Lopez-Bastida J, Aranda-Reneo I, Rodriguez-Sanchez B, Pena-Longobardo LM, Ye X, Laeis P, et al. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. Orphanet J Rare Dis. 2021;16:294. https:\/\/doi.org\/10.1186\/s13023-021-01883-5.","journal-title":"Orphanet J Rare Dis"},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1093\/oncolo\/oyad011","volume":"28","author":"E Palmerini","year":"2023","unstructured":"Palmerini E, Healey JH, Bernthal NM, Bauer S, Schreuder H, Leithner A, et al. Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry: a 2- year analysis of patient- reported outcomes and treatment strategies. Oncologist. 2023;28:e425\u201335. https:\/\/doi.org\/10.1093\/oncolo\/oyad011.","journal-title":"Oncologist"},{"key":"1679_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11912-020-00926-7","volume":"22","author":"NM Bernthal","year":"2020","unstructured":"Bernthal NM, Ishmael CR, Burke ZDC. Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon\u2019s perspective. Curr Oncol Rep. 2020;22:63. https:\/\/doi.org\/10.1007\/s11912-020-00926-7.","journal-title":"Curr Oncol Rep"},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-024-02674-y","volume":"132","author":"AJ Hayes","year":"2025","unstructured":"Hayes AJ, Nixon IF, Strauss DC, Seddon BM, Desai A, Benson C, et al. UK guidelines for the management of soft tissue sarcomas. Br J Cancer. 2025;132:11\u201331. https:\/\/doi.org\/10.1038\/s41416-024-02674-y.","journal-title":"Br J Cancer"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.36469\/jheor.2022.32485","volume":"9","author":"F Lin","year":"2022","unstructured":"Lin F, Kwong WJ, Shi S, Pivneva I, Wu EQ, Abraham JA. Surgical treatment patterns, healthcare resource utilization, and economic burden in patients with tenosynovial giant cell tumor who underwent joint surgery in the United States. J Health Econ Outcomes Res. 2022;9:68\u201374. https:\/\/doi.org\/10.36469\/jheor.2022.32485.","journal-title":"J Health Econ Outcomes Res"},{"key":"1679_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jso.26991","volume":"126","author":"G Spierenburg","year":"2022","unstructured":"Spierenburg G, van der Heijden L, Mastboom MJL, van Langevelde K, van der Wal RJP, Gelderblom H, et al. Surgical management of 144 diffuse-type TGCT patients in a single institution: a 20-year cohort study. J Surg Oncol. 2022;126:1087\u201395. https:\/\/doi.org\/10.1002\/jso.26991.","journal-title":"J Surg Oncol"},{"key":"1679_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.knee.2017.04.019","volume":"24","author":"MT Houdek","year":"2017","unstructured":"Houdek MT, Scorianz M, Wyles CC, Trousdale RT, Sim FH, Taunton MJ. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis. Knee. 2017;24:851\u20135. https:\/\/doi.org\/10.1016\/j.knee.2017.04.019.","journal-title":"Knee"},{"key":"1679_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.arth.2017.12.030","volume":"33","author":"ME Tibbo","year":"2018","unstructured":"Tibbo ME, Wyles CC, Rose PS, Sim FH, Houdek MT, Taunton MJ. Long- term outcome of hip arthroplasty in the setting of pigmented villonodular synovitis. J Arthroplasty. 2018;33:1467\u201371. https:\/\/doi.org\/10.1016\/j.arth.2017.12.030.","journal-title":"J Arthroplasty"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"107953","DOI":"10.1016\/j.ejso.2024.107953","volume":"50","author":"G Spierenburg","year":"2024","unstructured":"Spierenburg G, Staals EL, Palmerini E, Randall RL, Thorpe SW, Wunder JS, et al. Active surveillance of diffuse-type tenosynovial giant cell tumors: a retrospective, multicenter cohort study. Eur J Surg Oncol. 2024;50:107953. https:\/\/doi.org\/10.1016\/j.ejso.2024.107953.","journal-title":"Eur J Surg Oncol"},{"key":"1679_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdn033","volume":"19","author":"JY Blay","year":"2008","unstructured":"Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT). Ann Oncol. 2008;19:821\u20132. https:\/\/doi.org\/10.1093\/annonc\/mdn033.","journal-title":"Ann Oncol"},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","volume":"9","author":"FGM Verspoor","year":"2019","unstructured":"Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, et al. Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor. Sci Rep. 2019;9:14551. https:\/\/doi.org\/10.1038\/s41598-019-51211-y.","journal-title":"Sci Rep"},{"key":"1679_CR22","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer. 2012;118:1649\u201355. https:\/\/doi.org\/10.1002\/cncr.26409.","journal-title":"Cancer"},{"key":"1679_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","volume":"19","author":"H Gelderblom","year":"2018","unstructured":"Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19:639\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(18)30143-8.","journal-title":"Lancet Oncol"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","volume":"173","author":"G Spierenburg","year":"2022","unstructured":"Spierenburg G, Grimison P, Chevreau C, Stacchiotti S, Piperno-Neumann S, Le Cesne A, et al. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: long-term follow-up of nilotinib in TGCT. Eur J Cancer. 2022;173:219\u201328. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.028.","journal-title":"Eur J Cancer"},{"key":"1679_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R Inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(15)00132-1.","journal-title":"Lancet Oncol"},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","volume":"141","author":"PA Cassier","year":"2020","unstructured":"Cassier PA, Italiano A, Gomez-Roca C, Le Tourneau C, Toulmonde M, D\u2019Angelo SP, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. Eur J Cancer. 2020;141:162\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.038.","journal-title":"Eur J Cancer"},{"key":"1679_CR27","unstructured":"TURALIO\u00ae (pexidartinib) capsules, for oral use [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; October 2021."},{"key":"1679_CR28","unstructured":"Korean Ministry of Food and Drug Safety. 2021 drug approval report. 2022. https:\/\/www.mfds.go.kr\/eng\/brd\/m_19\/down.do?brd_id=eng0004&seq=70437&data_tp=A&file_seq=1"},{"key":"1679_CR29","unstructured":"Taiwan Food and Drug Administration. Pexidartinib assessment report. 2022. https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?mid=189&id=41072&t=s"},{"key":"1679_CR30","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): soft tissue sarcoma version 5.2024 \u2014 March 10, 2025. Accessed March 20, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf."},{"key":"1679_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373:428\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1411366.","journal-title":"N Engl J Med"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","volume":"28","author":"WD Tap","year":"2022","unstructured":"Tap WD, Singh AS, Anthony SP, Sterba M, Zhang C, Healey JH, et al. Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT. Clin Cancer Res. 2022;28:298\u2013307. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2007.","journal-title":"Clin Cancer Res"},{"key":"1679_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394:478\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(19)30764-0.","journal-title":"Lancet"},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","volume":"92","author":"M Van De Sande","year":"2021","unstructured":"Van De Sande M, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, et al. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Acta Orthop. 2021;92:493\u20139. https:\/\/doi.org\/10.1080\/17453674.2021.1922161.","journal-title":"Acta Orthop"},{"key":"1679_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CORR.0000000000002335","volume":"481","author":"JH Healey","year":"2023","unstructured":"Healey JH, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, et al. Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: results from ENLIVEN. Clin Orthop Relat Res. 2023;481:107\u201316. https:\/\/doi.org\/10.1097\/CORR.0000000000002335.","journal-title":"Clin Orthop Relat Res"},{"key":"1679_CR36","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.33312","volume":"127","author":"H Gelderblom","year":"2021","unstructured":"Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2021;127:884\u201393. https:\/\/doi.org\/10.1002\/cncr.33312.","journal-title":"Cancer"},{"key":"1679_CR37","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1002\/onco.13629","volume":"26","author":"JH Lewis","year":"2021","unstructured":"Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, et al. Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors. Oncologist. 2021;26:e863\u201373. https:\/\/doi.org\/10.1002\/onco.13629.","journal-title":"Oncologist"},{"key":"1679_CR38","unstructured":"Wagner J et al. Paper 47 - long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: results from the phase 3 ENLIVEN study. Presented at Connective Tissue Oncology Society (CTOS) Annual Meeting; November 16-19, 2022; Vancouver, Canada."},{"key":"1679_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40487-024-00298-z","volume":"12","author":"E Palmerini","year":"2024","unstructured":"Palmerini E, Peta G, Tuzzato G. Pexidartinib upfront in a case of tenosynovial giant cell tumor: proof of concept for a treatment paradigm shift. Oncol Ther. 2024;12:833\u201341. https:\/\/doi.org\/10.1007\/s40487-024-00298-z.","journal-title":"Oncol Ther"},{"key":"1679_CR40","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1080\/14796694.2024.2373687","volume":"20","author":"C Dharmani","year":"2024","unstructured":"Dharmani C, Fofah O, Fallon M, Rajper AW, Wooddell M, Salas M. TURALIO((R)) Risk Evaluation and Mitigation Strategy program (tREMS): 3-year retrospective hepatic safety assessment. Future Oncol. 2024;20:2559\u201364. https:\/\/doi.org\/10.1080\/14796694.2024.2373687.","journal-title":"Future Oncol"},{"key":"1679_CR41","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1093\/oncolo\/oyad282","volume":"29","author":"F Lin","year":"2024","unstructured":"Lin F, Jacqueline Kwong W, Pan I, Ye X, Dai D, Tap W. Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor. Oncologist. 2024;29:e535\u201343. https:\/\/doi.org\/10.1093\/oncolo\/oyad282.","journal-title":"Oncologist"},{"key":"1679_CR42","unstructured":"Dai D, Lin F, Pan I, Freivogel K, Ye X, Tecson K et al. Patient-reported continued benefits in patients treated with pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States. Poster presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting; November 1-4, 2023;Dublin, Ireland."},{"key":"1679_CR43","doi-asserted-by":"publisher","first-page":"e35634","DOI":"10.1002\/cncr.35634","volume":"131","author":"J Desai","year":"2025","unstructured":"Desai J, Wagner AJ, Carrasco Garcia I, Cesari M, Gordon M, Lin CC, et al. A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib. Cancer. 2025;131:e35634. https:\/\/doi.org\/10.1002\/cncr.35634.","journal-title":"Cancer"},{"key":"1679_CR44","doi-asserted-by":"publisher","first-page":"128928","DOI":"10.1016\/j.bmcl.2022.128928","volume":"74","author":"TM Caldwell","year":"2022","unstructured":"Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, et al. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of tenosynovial giant cell tumor (TGCT). Bioorg Med Chem Lett. 2022;74:128928. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128928.","journal-title":"Bioorg Med Chem Lett"},{"key":"1679_CR45","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","volume":"30","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Razak AA, Taylor MH, Bauer TM, Wilky B, Martin-Broto J, et al. CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: a phase I study of vimseltinib. Clin Cancer Res. 2024;30:3996\u20134004. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0103.","journal-title":"Clin Cancer Res"},{"key":"1679_CR46","unstructured":"ROMVIMZA (vimseltinib) capsules, for oral use. [highlights of prescribing information]. Deciphera Pharmaceuticals; 2025."},{"key":"1679_CR47","unstructured":"Blay J, Rutkowski P, Gelderblom H, Stacchiotti S, Falcon Gonzalez A, Desai J et al. Safety, efficacy, and patient-reported outcomes withvimseltinib in patients with tenosynovial giant cell tumorwho received no prior anti\u2013colony-stimulating factor 1therapy: ongoing phase 2 update (P176). Presented at Connective Tissue Oncology Society (CTOS) Annual Meeting; November 1-4, 2023; Dublin, Ireland."},{"key":"1679_CR48","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","volume":"403","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403:2709\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00885-7.","journal-title":"Lancet"},{"key":"1679_CR49","unstructured":"FDA ROMVIMZA approval letter. NDA 219304. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/219304Orig1s000ltr.pdf"},{"key":"1679_CR50","doi-asserted-by":"publisher","unstructured":"Niu X, Ravi V, Shan B, Guo Q, Shi H, Zou Q, et al. MANEUVER: a phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients. Future Oncol. 2024;1\u20138. https:\/\/doi.org\/10.1080\/14796694.2024.2396227.","DOI":"10.1080\/14796694.2024.2396227"},{"key":"1679_CR51","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1200\/JCO.2023.41.16_suppl.11559","volume":"41","author":"L Yao","year":"2023","unstructured":"Yao L, et al. Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): phase 1b update. J Clin Oncol. 2023;41:1159. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.11559.","journal-title":"J Clin Oncol"},{"key":"1679_CR52","unstructured":"Merck KGaA. Pimicotinib significantly improved outcomes for patients with TGCT in phase III trial. 2024. Accessed March 4, 2025. https:\/\/www.emdgroup.com\/en\/news\/pimicotinib-topline-results-12-11-2024.html."},{"key":"1679_CR53","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/fon-2023-0363","volume":"20","author":"C Dharmani","year":"2024","unstructured":"Dharmani C, Fofah O, Wang E, Salas M, Wooddell M, Tu N, et al. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA. Future Oncol. 2024;20:1079\u201397. https:\/\/doi.org\/10.2217\/fon-2023-0363.","journal-title":"Future Oncol"},{"key":"1679_CR54","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.suronc.2018.07.002","volume":"27","author":"MJL Mastboom","year":"2018","unstructured":"Mastboom MJL, Verspoor FGM, Hanff DF, Gademan MGJ, Dijkstra PDS, Schreuder HWB, et al. Severity classification of tenosynovial giant cell tumours on MR imaging. Surg Oncol. 2018;27:544\u201350. https:\/\/doi.org\/10.1016\/j.suronc.2018.07.002.","journal-title":"Surg Oncol"},{"key":"1679_CR55","unstructured":"TGCT Support. https:\/\/www.tgctsupport.org\/. Accessed March 14, 2025."},{"key":"1679_CR56","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2217\/fon-2020-0307","volume":"16","author":"W Tap","year":"2020","unstructured":"Tap W. ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020;16:1875\u20138. https:\/\/doi.org\/10.2217\/fon-2020-0307.","journal-title":"Future Oncol"},{"key":"1679_CR57","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1080\/14796694.2024.2398893","volume":"20","author":"NM Bernthal","year":"2024","unstructured":"Bernthal NM, Stern S, Blay J-Y. Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial. Future Oncol. 2024;20:3183\u201392. https:\/\/doi.org\/10.1080\/14796694.2024.2398893.","journal-title":"Future Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01679-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T02:20:56Z","timestamp":1754533256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01679-x","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"15 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"E.P. has served on advisory boards for Daiichi Sankyo, Deciphera, Eusa Pharma, SynOx Therapeutics, Ipsen, and Servier, outside the submitted work. J.C.T. has served as a consultant for Bayer, Deciphera, Adcendo, Daiichi Sankyo, and Ipsen. F.J.H. has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}